Finanztrends
Deine Einschätzung
Was spricht für und gegen Advanced Proteome Therapeutics in den nächsten Jahren?
Pro
?
M****
?
L*********** I********** f** d** n******* J****
?
A****************
Kontra
?
M************
?
U****************
?
W******* i* V********
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Advanced Proteome Therapeutics im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Advanced Proteome Therapeutics | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | -1,04 % | -3,55 % | -13,64 % | 108,79 % | 14,46 % | 2,15 % | -68,60 % |
| Vaxart Inc. | 42,86 % | 9,09 % | -4,76 % | 59,24 % | 114,29 % | -13,12 % | -88,24 % |
| Celldex Therapeutics | 6,25 % | 1,49 % | 6,25 % | 64,85 % | 23,64 % | -16,41 % | 56,77 % |
News
This New Spinoff Is a Nuclear and AI Chip Beneficiary Worth Watching
Solstice Advanced Materials (NASDAQ: SOLS) is a relatively new stock to the market, but one that has gotten off to a blistering start. At the end of October 2025, the over $100 billion
Stock Market Today, March 31: Nvidia Rises on $2 Billion Marvell AI Infrastructure Partnership
Nvidia (NASDAQ:NVDA), a leader in GPUs and AI computing platforms, closed Tuesday at $174.40, up 5.59%. The stock moved higher after news of a $2 billion Marvell Technology investment and expanded
Your Artificial Intelligence (AI) Portfolio Probably Looks Very Different Than It Did 6 Months Ago. Here's Why That's OK.
If you have had a heavy artificial intelligence (AI) position over the last year or two, it probably included many of the same names: Nvidia, Advanced Micro Devices, Microsoft, a few hyperscalers